Loading clinical trials...
Loading clinical trials...
A Phase I, First in Human (FIH), Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients With Advanced/Metastatic Solid Tumors
Conditions
Interventions
TJ101
Locations
7
United States
Florida Cancer Specialists & Research Institute
Orlando, Florida, United States
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee, United States
Oncology Consultants
Houston, Texas, United States
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital of Tongji Medical College
Wuhan, Hubei, China
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Start Date
August 25, 2025
Primary Completion Date
December 30, 2026
Completion Date
September 15, 2027
Last Updated
January 12, 2026
NCT06713993
NCT06594926
NCT06257264
NCT00242723
NCT05939414
NCT03620786
Lead Sponsor
Phrontline Biopharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions